{
    "code": 0,
    "data": [
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of the revised presentation that would be used in the Investors/ Analysits call on Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31 2025 to be held today i.e February 10 2026 at 8.30 a.m.",
            "news_id": "07076a3c-9a0b-49d4-bb49-ae7157e3b293",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=04527598-c3a8-4c8c-a952-b486638c9178.pdf",
            "news_date": "2026-02-10 06:58:15",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of investor presentation on unaudited financial results for the quarter and nine months period ended December 31 2025.",
            "news_id": "d8514771-f823-43a9-bbbb-f4b36d014f2c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca5c35e2-908b-4fbc-94d1-07553c6f2594.pdf",
            "news_date": "2026-02-09 19:50:38",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter  And Nine Months Ended December 31 2025",
            "news_body": "Submission of unaudited financial results for the quarter and nine months period ended December 31 2025.",
            "news_id": "eb37caf6-5318-43f0-ab43-1d55c4c38a30",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3d9a63a-1119-42ea-a844-2814388d6a99.pdf",
            "news_date": "2026-02-09 19:36:56",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of earning call transcript.",
            "news_id": "c4f1f090-997c-48c1-ba7a-48f75184e7d1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38fa1702-0014-46be-805a-43fd18f17cc1.pdf",
            "news_date": "2025-11-11 17:01:33",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Presentation on Unaudited Financial Results of the Company for the second quarter and half year ended 30.09.2025",
            "news_id": "ae039f02-8dc5-4ca7-bced-b170229c336b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3f251a0-a55f-47f8-88cf-8e712f9ff554.pdf",
            "news_date": "2025-11-05 20:00:09",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of transcript of earnings call on the Unaudited Financial Results for the first quarter ended June 30. 2025.",
            "news_id": "4b6e84e5-f88d-458a-a4b4-affe6bae40d6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cba3da3b-6c58-4ea1-99f1-5853086d9a8a.pdf",
            "news_date": "2025-08-08 12:07:00",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of Investor Presentation that would be used in the investors/analyst call on unaudited financial results of the Company for the first quarter ended June 302025",
            "news_id": "8f070f2a-1da3-4ec2-8944-b30faefae25d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8315ee0f-ddb9-4da4-808f-ca32938618e5.pdf",
            "news_date": "2025-08-04 19:46:17",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of earning call transcript .",
            "news_id": "19a2d8ea-7567-4f73-8e38-4d3963791b4e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=18df2504-0212-4327-971e-954b70abb3bf.pdf",
            "news_date": "2025-06-02 16:57:00",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of Earnings Presentation on Audited Financial Results for the quarter and year ended March 31 2025.",
            "news_id": "9a810ebb-66e6-44e7-abc4-88db31491033",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=052022b5-95e0-45ba-bf01-6c1db76b5d9f.pdf",
            "news_date": "2025-05-26 20:08:06",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of Q3 of FY2025 earnings call  transcript",
            "news_id": "a99c94e6-e6ed-4dea-a9cf-8f05302496e0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a1fdc43-c10e-460c-a60f-512ed9cd4218.pdf",
            "news_date": "2025-02-13 12:05:21",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of Investor Presentation",
            "news_id": "3e469fcd-11f1-49c0-b344-836788df4b7d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3de8a0cf-c364-4b5e-b51b-03e67ce5e338.pdf",
            "news_date": "2025-02-06 20:22:43",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Period Ended December 31 2024",
            "news_body": "submission of Unaudited financial results for the quarter and nine months period ended December 31 2024",
            "news_id": "453e48e5-b79c-437a-b037-890a0629f9a1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b4858ffa-bfde-4404-aeeb-3490d94ee738.pdf",
            "news_date": "2025-02-06 19:56:52",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of Transcript of Earnings Call on Unaudited financial Results for the Quarter and Half Year ended  30th September 2024.",
            "news_id": "91f45d47-c400-46b1-a9a8-75591bbfb4e9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5216098b-a943-44ca-a1ab-72094c7f334c.pdf",
            "news_date": "2024-11-18 11:07:10",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated November 4, 2024, please note that the audio recording of the earnings call on the Unaudited Financial Results for the second quarter and half year ended September 30, 2024, held on November 11, 2024 at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings",
            "news_id": "212a14fc-08be-4e2a-9ee7-a712752023c7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87f24c7f-72f4-461e-b38e-153d9e7c0b68.pdf",
            "news_date": "2024-11-11 15:08:05",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended September 30,2024",
            "news_body": "Submitting the Unaudited Financial Results for the quarter and half year ended September 30, 2024",
            "news_id": "12729d3a-79c1-44e3-83f0-ee65adfe0d50",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cf565e81-c3f3-45e8-9586-5c9e45810c1e.pdf",
            "news_date": "2024-11-09 19:13:33",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "We enclose the presentation on Unaudited Financial Results for the quarter and half year ended September 30, 2024",
            "news_id": "098c2abc-cd46-4996-b861-9b8f9a6a0fa7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09f46763-3228-4857-a164-39bea5713450.pdf",
            "news_date": "2024-11-09 19:07:26",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of Transcript of Earning call on unaudited financial results of Q1 2024-25.",
            "news_id": "5209be2a-706a-4afa-ba09-88347b757dcd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2fa5dd59-59af-4bda-af84-37083f4141c5.pdf",
            "news_date": "2024-08-16 15:13:46",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated August 5, 2024, please note that the audio recording of the earnings call on the Unaudited Financial Results for the first quarter ended June 30, 2024, held on August 12, 2024, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings",
            "news_id": "c06b7932-b541-47db-954b-4d54121ec358",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=be0eb07c-3a93-4133-96e4-2267ab87f265.pdf",
            "news_date": "2024-08-12 15:14:23",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of Investor Presentation on Unaudited Financial Results for Q1 of FY 2024-25.",
            "news_id": "1290bb46-607a-40a1-a438-e62c405285c6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85e2064d-1ff4-4242-8f5a-1a8f7cbd0008.pdf",
            "news_date": "2024-08-10 18:45:33",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Submission Of Unaudited Financial Results For The 1St Quarter Of FY 2024-25",
            "news_body": "Submission of Unaudited Financial Results for the 1st Quarter of FY 2024-25",
            "news_id": "fccf0113-0630-4ca2-baed-c7dd34b22c9b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5e7a039b-972f-487b-95d0-cc4b16667232.pdf",
            "news_date": "2024-08-10 18:33:21",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of transcript of earnings call held on May 27, 2024 on audited financial results for the fourth quarter and year ended on March 31, 2024.",
            "news_id": "7d76d78d-19db-4c65-aa50-1438467cd54f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fefdeb36-1743-418d-a02e-7f05451a69b3.pdf",
            "news_date": "2024-05-31 18:29:03",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Submission of Audio recording of earnings call held on 27th May 2024 on Audited Financial Results for the year ended 31st March 2024.",
            "news_id": "f743e809-d2a0-4c34-90cf-2dd850a1611d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d34977e0-1615-4406-9e54-5fccad598fff.pdf",
            "news_date": "2024-05-27 16:36:04",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Submission of Investors Presentation on audited financial results for the financial year ended March 31, 2024",
            "news_id": "21a03e9a-f534-40ee-a893-be4de4496b0e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=954eae16-10a4-457a-bc5a-9a6f36765cd6.pdf",
            "news_date": "2024-05-25 19:20:56",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31, 2024",
            "news_body": "Submission of Audited Financial Results for the fourth quarter and financial year ended on March 31, 2024",
            "news_id": "32cac090-d4aa-484b-8b8c-ecb7ca460c8e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3848890-121a-4ed6-843b-9060ee78da91.pdf",
            "news_date": "2024-05-25 19:01:30",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Weblink of Investor Presentation",
            "news_id": "5e55e5fa-e3e8-4286-bdaf-aeb670248992",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=68a574d2-96b6-4657-9123-ad4fdbcac35c.pdf",
            "news_date": "2024-03-13 11:31:56",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Submission of Earnings Call Transcript on Q3 FY2023-24",
            "news_id": "08cda593-1595-42d4-a4e5-9b00c5d66749",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06a705ce-0ecd-42a2-bb8e-6750a29e8330.pdf",
            "news_date": "2024-02-16 15:21:29",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of Earnings Call held on 12th February 2024 on Q3FY24 Unaudited Financial Results",
            "news_id": "c5b63eff-4d31-4bb7-a70d-cb070638346b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5d809f63-348a-479d-9374-7c2b35b90cb7.pdf",
            "news_date": "2024-02-12 12:45:22",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on Unaudited Financial Results for the quarter and nine months period ended on 31st December 2023",
            "news_id": "abb91e91-ece7-456a-a181-cfece7e8da77",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b61725fe-095c-49a9-8a0d-b24dc2790adf.pdf",
            "news_date": "2024-02-10 18:12:49",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter Ended 31St December 2023",
            "news_body": "Submission of Financial Results for the quarter and nine months period ended 31st December 2023",
            "news_id": "53f5258b-b09f-49de-9d82-5bf07db15ad1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c3eefd9-9115-41d0-b85e-c887c6a927aa.pdf",
            "news_date": "2024-02-10 17:41:36",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Intimation Of Outcome Of Board Meeting Held Today, February 10, 2024",
            "news_body": "Intimation of outcome of Board meeting held on February 10, 2024",
            "news_id": "d67086e4-ce86-4523-bdb2-f6546451b1cd",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f9eeec9a-7a60-42a9-b79f-5a948864135a.pdf",
            "news_date": "2024-02-10 17:35:27",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Q2FY24 Earnings Call held on November 10, 2023",
            "news_id": "e9eac057-4ba4-47d3-9159-4d53898fa90e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f332acf-b597-4c44-bc68-5d76f0f2e8de.pdf",
            "news_date": "2023-11-15 12:57:07",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30Th September 2023.",
            "news_body": "Unaudited Financial Results for the quarter ended 30th September 2023.",
            "news_id": "e462b54c-5176-41e1-911c-677003b49d97",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b9124436-aaa0-4139-94f9-468bf34bb532.pdf",
            "news_date": "2023-11-09 19:52:07",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earning Presentation on Q2FY24 Unaudited Financial Results",
            "news_id": "42baf8e8-9691-44b5-b08d-341f1939f24c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=49b09f51-72b3-4b61-86f1-681a090021a4.pdf",
            "news_date": "2023-11-09 19:46:54",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please find attached the earning call transcript for the quarter ended June 30, 2023.",
            "news_id": "004a0edb-8652-4116-ace4-dc6e7b0b4f67",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c652426c-06f6-4edf-bedf-8f5cd0466ef0.pdf",
            "news_date": "2023-08-18 12:45:38",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated August 4, 2023, please note that the audio recording of the earnings call on the unaudited financial results for the first quarter ended June 30, 2023, held on August 14, 2023, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/",
            "news_id": "0b9fcc1c-8989-4e65-a4f3-e4246f36a82e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5f94176f-de7c-4de3-982b-cefc8ac69c99.pdf",
            "news_date": "2023-08-14 13:09:08",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on un-audited financial results for the first quarter ended June 30, 2023.",
            "news_id": "a7528efc-6c2f-4f09-8959-ede1d28d6a3b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f63e36d-fb67-4bf0-97e7-f918e0a580fa.pdf",
            "news_date": "2023-08-12 18:32:59",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For The Quarter Ended June 30, 2023.",
            "news_body": "Un-audited financial results for the quarter ended June 30, 2023.",
            "news_id": "80cefc4d-e658-401c-96c0-794689b6ac06",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d663cb09-bb88-4b56-80f6-9651ff77c41f.pdf",
            "news_date": "2023-08-12 18:26:47",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated May 19, 2023, wherein we intimated about the schedule of Investors/ Analysts call onMay 29, 2023. We are attaching herewith the Transcript of the said analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2023, and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-call-transcripts/",
            "news_id": "83421466-b761-43ea-bb22-f1ff22aa4105",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c1598e6b-722b-44cb-97b1-4c0324acbdc8.pdf",
            "news_date": "2023-06-01 16:16:40",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated May 19, 2023, please note that the audio recording of the earnings call on the audited financial results for the fourth quarter and year ended March 31, 2023, held on May 29, 2023, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/",
            "news_id": "9ba1ef0c-e815-4a3d-b9a8-64f88648b368",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=90aec6e5-4037-4d79-b19c-7b5d273ab435.pdf",
            "news_date": "2023-05-29 15:13:07",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated May 19, 2023 wherein we intimated the schedule of Investors/ Analysts call on May 31, 2023.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2023.  The presentation is also being uploaded in the following weblink of the Company.",
            "news_id": "42475dd9-86d9-4dac-a3a0-094f411e30b1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c9ab1fc-bb0b-4148-ae91-5c1ccd9ecabc.pdf",
            "news_date": "2023-05-27 19:41:49",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For Mar 31, 2023",
            "news_body": "The Board of Directors of the Company at its meeting held today, May 27, 2023, has inter alia, considered andapproved the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and yearended March 31, 2023, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the AuditReports issued by the Statutory Auditors of the Company.Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditorsof the Company, M/s. Deloitte Haskins & Sells, Chartered Accountants, have issued the audit reports on Standaloneand Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2023, withunmodified opinion.",
            "news_id": "6b465205-1790-451a-aca1-5e659ffaf169",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4dc4d484-1e8e-4b5d-8477-eb90abd4ae72.pdf",
            "news_date": "2023-05-27 19:32:43",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of Q3 FY23 earnings call",
            "news_id": "e8b9481b-7033-4af1-b730-a6e80b53aa8c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0af27d5c-28a1-459e-b1ac-5782965241c4.pdf",
            "news_date": "2023-02-17 14:29:49",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated February 3, 2023, please note that the audio recording of the earnings call on the unaudited financial results for the third quarter and nine months period ended December 31, 2022, held on February 10, 2023, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/",
            "news_id": "26eabc6e-1cc9-45c6-9afc-f0535ad68ee2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c219ebc5-51dd-47ae-9806-7b60aeb480b4.pdf",
            "news_date": "2023-02-10 16:08:52",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor presentation on Q3 - 2022-23 earnings.",
            "news_id": "31924097-f484-4684-af6a-27771bf2f52f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=03756010-91f3-4aa6-aac2-9b29d33253c7.pdf",
            "news_date": "2023-02-09 19:58:20",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Aale And Transfer Of Units Constituting API Non-Antibiotic Division Of The Company To Auro Pharma India Private Limited, A Wholly Owned Subsidiary Of The Company",
            "news_body": "Please refer to our letter dated February 3, 2023 wherein we have intimated the schedule of Investors/ Analysts call on February 10, 2023.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the Third quarter and nine months period ended December 31, 2022.  The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations/",
            "news_id": "77b194bb-70e1-4e01-a36e-82db687eb603",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a9a78e3-2d6f-4af4-9d91-93f288d7cbed.pdf",
            "news_date": "2023-02-09 19:32:23",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Aale And Transfer Of Units Constituting API Non-Antibiotic Division Of The Company To Auro Pharma India Private Limited, A Wholly Owned Subsidiary Of The Company",
            "news_body": "Please refer to our letter dated February 3, 2023 wherein we have intimated the schedule of Investors/ Analysts call on February 10, 2023.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the Third quarter and nine months period ended December 31, 2022.  The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations/",
            "news_id": "8c7499b9-b1d7-42b0-8ecc-052cb1eda285",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d3f7a93-f47b-44d5-b5b5-aabf047e54c4.pdf",
            "news_date": "2023-02-09 19:19:58",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Period Ended 31.12.2022",
            "news_body": "The Board of Directors of the Company at its meeting held today, February 9, 2023, has inter alia, transacted the following items of business:<BR> <BR> 1.  Approved the standalone and consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Unaudited Financial Results of the Company along with the Limited Review Report issued by the Statutory Auditors.<BR> <BR> 2.  Approved first interim dividend of 300% i.e. Rs.3.00 (Rupees three only) per equity share of Re.1/- each on the equity share capital of the Company. The Company has already fixed February 17, 2023 as the record date for the purpose of payment of interim dividend for the financial year 2022-23. The interim dividend will be paid on or before March 3, 2023.<BR> <BR>",
            "news_id": "7fda3a54-46a6-40a8-a269-b6255a97275a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2eed77e-6f8c-4063-a22f-037420f6fb7a.pdf",
            "news_date": "2023-02-09 18:51:21",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended 30Th September 2022",
            "news_body": "Pursuant to Regulation 23(9) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith disclosure on Related Party Transactions for the half year ended September 30, 2022.The above disclosure is also being updated on the Company's website www.aurobindo.com",
            "news_id": "19c93104-5ab9-43a9-b200-3eb06bad6752",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f10ac60-fda7-4da7-acf8-2e7e58fa850f.pdf",
            "news_date": "2022-11-25 23:40:26",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended 30Th September 2022",
            "news_body": "Pursuant to Regulation 23(9) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith disclosure on Related Party Transactions for the half year ended September 30, 2022. The above disclosure is also being updated on the Company's website www.aurobindo.com",
            "news_id": "4f9330ee-5e98-44a1-8e53-83e3cd4aef36",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27e6ac98-66f7-419f-b179-ed51cd5ad05d.pdf",
            "news_date": "2022-11-25 23:34:09",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Sub: Transcript of Q2FY23 earnings call.Please refer to our letter dated November 8, 2022 wherein we intimated about the schedule of Investors/ Analysts call on November 14, 2022. We are attaching herewith the Transcript of the said analyst / investor call on the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-call-transcripts/Please take the information on record.",
            "news_id": "eebb4ce6-c534-4484-8ca5-f38214ca562c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7c69553-0feb-4b65-a2d1-3ec716f38c63.pdf",
            "news_date": "2022-11-18 16:23:37",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated November 8, 2022, please note that the audio recording of the earnings call on the unaudited financial results for the second quarter and half year ended September 30, 2022, held on November 14, 2022, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/",
            "news_id": "e7df7952-c571-4a42-8e8c-c2b79bb23c72",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=128d9461-3813-4aa1-91e4-436e37b3031c.pdf",
            "news_date": "2022-11-14 16:41:21",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated November 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on November 14, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the Second quarter and half year ended September 30, 2022.The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations/",
            "news_id": "0023329c-c757-42ac-b4ba-f76c53b22a19",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2153e0d0-7afc-444f-8458-d866a4fbcbd2.pdf",
            "news_date": "2022-11-12 17:55:58",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Second Quarter And Half Year Ended 30.09.2022",
            "news_body": "The Board of Directors of the Company at its meeting held today, November 12, 2022, has, inter alia, considered and<BR> approved the Un-audited Financial Results of the Company for the Second Quarter and half year ended September<BR> 30, 2022 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.<BR> We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory<BR> Auditors of the Company.<BR> The Board meeting commenced at 2.30 p.m. and concluded at 5.05 p.m.",
            "news_id": "a10a8bda-43a3-4e6c-ab97-f5c23f931da5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c71d934e-0b76-4153-ad98-37a2bb4fcc19.pdf",
            "news_date": "2022-11-12 17:31:00",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Further to our letter dated September 6, 2022 informing about the participation in the Kotak Institutional Equity Healthcare Forum 2022 on September 8, 2022, we inform you that the presentation updated in the following weblink of the Company will be used during the interaction with the investors.https://www.aurobindo.com/wp-content/uploads/2022/09/Aurobindo-Pharma_Investor-Presentation_INR_Sep-22.pdfNo unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.",
            "news_id": "d73310bd-06c7-410d-86a4-b737bc1d5f3b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8073fada-0372-4208-9207-3a8c04b0872f.pdf",
            "news_date": "2022-09-07 16:11:45",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated August 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on August 12, 2022. We are attaching herewith the Transcript of the analyst / investor call on the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/",
            "news_id": "1b06c7bf-96f1-4eb8-b2ee-676545351532",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2121b890-a348-4e99-a006-d44e721e2756.pdf",
            "news_date": "2022-08-19 17:19:11",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call Conducted On August 12, 2022",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated August 8, 2022, please note that the audio recording of the earnings call  on the unaudited financial results for the first quarter ended June 30, 2022, held on August 12, 2022, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/wp-content/uploads/2022/08/audio1190421139.mp3",
            "news_id": "ca574ac7-de69-456c-a378-da032295b9ea",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=49c5f4cb-3b12-4133-86c6-d4a46740888c.pdf",
            "news_date": "2022-08-12 16:06:04",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated August 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on August 12, 2022.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first quarter ended June 30, 2022.  The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/",
            "news_id": "19dad558-05b7-49f1-9b99-aeb9b036af2f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=68697592-bf02-4c82-91c6-077e5e839ed3.pdf",
            "news_date": "2022-08-11 17:58:01",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended June 30.2022",
            "news_body": "The Board of Directors of the Company at its meeting held today, August 11, 2022, has, inter alia, considered and approved the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2022 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.<BR> <BR> We also enclose a copy of the Press Release on the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2022.",
            "news_id": "f56dba25-ff48-48cb-ae57-5d639c648928",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9e4207f3-3476-4372-972b-2c8a1d3f2c1c.pdf",
            "news_date": "2022-08-11 17:39:50",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2022",
            "news_body": "Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed disclosure of Related Party Transactions for the half year ended March 31, 2022.",
            "news_id": "3b6877b5-15c0-468c-b471-c563cd59af93",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=80993276-f5d4-47e1-99ec-bc49805d6906.pdf",
            "news_date": "2022-06-14 16:56:34",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated May 26, 2022 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2022. We are attaching herewith the Transcript of the analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/",
            "news_id": "88a0124d-8dfd-4e63-b382-acacc071f66f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2d34ef9-ded8-4cdb-ab71-41718ce10034.pdf",
            "news_date": "2022-06-06 16:34:22",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "General",
            "cat": "Audio",
            "caption": "Audio Recording Of Earnings Call",
            "news_body": "Pursuant to Regulation 30 of SEBI Listing Regulations, and further to our letter dated May 26, 2022, please note that the audio recording of the earnings call for the fourth quarter and financial year ended March 31, 2022, held on May 31, 2022, at 8.30 AM (IST) has been uploaded on our website on the following web-link:https://www.aurobindo.com/wp-content/uploads/2022/05/Aurobindo-Q4-.mp3",
            "news_id": "91bbfa6b-a779-4da2-8d9f-885523673f04",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5a6167eb-4617-4bb7-9b26-8782fabac42c.pdf",
            "news_date": "2022-05-31 18:05:18",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Rsults For The Fourth Quarter And Year Ended 31.03.2022",
            "news_body": "The Board of Directors of the Company at its meeting held today, May 30, 2022, has inter alia, approved the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors. Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditors of the Company, M/s. B S R & Associates LLP, Chartered Accountants, have issued the audit report on Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2022, with unmodified opinion.<BR>",
            "news_id": "0488d934-31f7-4031-950a-7aba708f5c92",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e0c47650-484b-45eb-abf9-f7e53fc9df54.pdf",
            "news_date": "2022-05-30 20:32:59",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated May 26, 2022 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2022.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022.  The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/",
            "news_id": "9d76cb37-ce45-4bf6-99b6-e5783d90235f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee34978c-fd37-4f28-9d9d-49f68e3dc7e2.pdf",
            "news_date": "2022-05-30 20:10:25",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated February 3, 2022 wherein we have intimated the schedule of Investors/ Analysts call on February 10, 2022. We are attaching herewith the Transcript of the analyst / investor call on the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2021 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/",
            "news_id": "44941360-b654-41a4-b48f-d402c9e03e70",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=abeeed9c-cd30-4a8b-8d4b-77fc0e90873d.pdf",
            "news_date": "2022-02-17 11:48:09",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated February 3, 2022 wherein we have intimated the schedule of Investors/ Analysts call on February 10, 2022.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2021.  The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/",
            "news_id": "9c763b61-b9c2-4dd1-855a-7b4f2fa33142",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=57af06ee-eacc-457c-a6b0-45398714c79d.pdf",
            "news_date": "2022-02-09 18:15:29",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Period Ended 31.12.2021.",
            "news_body": "The Board of Directors of the Company at its meeting held today, February 9, 2022, has, inter alia,  considered and approved:- <BR> <BR> 1. the Un-audited Financial Results of the Company for the Third Quarter and nine months period ended December 31, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company; and<BR> <BR> 2.  a Third Interim Dividend @ 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2021-22. The Company has fixed February 21, 2022 as the Record Date for the purpose of payment of Third Interim Dividend and the same will be paid on or before March 4, 2022. <BR>",
            "news_id": "2fed36e9-01b9-41e0-b279-9aecf084a050",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=97e3ecf2-aab3-4b8c-9120-21f831f5d921.pdf",
            "news_date": "2022-02-09 17:56:59",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated November 2, 2021 wherein we have intimated the schedule of Investors/ Analysts call on November 9, 2021. We are attaching herewith the Transcript of the analyst / investor call on the Un-audited Financial Results of the Company for the second quarter and half year ended September 30, 2021 and the same is being uploaded on the website of the Company and is available in the following web link.<BR> <BR> https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/<BR>",
            "news_id": "4ba80d56-1284-406d-b141-e0673feef442",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61038607-118e-4fc6-8d04-21e7bbb1f5b7.pdf",
            "news_date": "2021-11-19 15:08:33",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated November 2, 2021 wherein we have intimated the schedule of Investors/ Analysts call on November 9, 2021.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the second quarter and half year ended September 30, 2021.  The presentation is also being uploaded in the following weblink of the Company.",
            "news_id": "4c2791b7-5c2a-4704-b15c-b5f5d39f82dc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2fb45cd-361e-46dd-981a-fd5e0f0b005e.pdf",
            "news_date": "2021-11-08 20:12:08",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For The  Second Quarter And Half Year Ended September 30, 2021",
            "news_body": "The Board of Directors of the Company at its meeting held today, November 8, 2021, has, inter alia,  considered and approved the Un-audited Financial Results of the Company for the Second Quarter and half year ended September 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company; <BR>",
            "news_id": "7dd92742-4348-4d1c-bffa-3e82364fbbf8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a919a350-9a61-455f-9a11-0884b39acf6e.pdf",
            "news_date": "2021-11-08 19:37:46",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On November 8, 2021.",
            "news_body": "The Board of Directors of the Company at its meeting held today, November 8, 2021, has, inter alia,  considered and approved:- <BR> <BR> 1. the Un-audited Financial Results of the Company for the Second Quarter and half year ended September 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company;<BR> <BR> 2.  a Second Interim Dividend @ 150% i.e Rs.1.50  (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2021-22. The Company has fixed November 18, 2021 as the Record Date for the purpose of payment of Second Interim Dividend and the same will be paid on or before November 30, 2021.<BR> <BR> We also enclose a copy of the Press Release on Un-audited Financial Results of the Company for the Second Quarter and half year ended September 30, 2021.<BR> <BR>",
            "news_id": "1494f542-46f6-4379-8fd1-b840cad67041",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61e29b8f-c5bf-4fb3-8624-0e92abe756dc.pdf",
            "news_date": "2021-11-08 19:27:08",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated August 7, 2021 wherein we have intimated the schedule of Investors/ Analysts call on August 13, 2021. We are attaching herewith the Transcript of the analyst / investor call on the Un-audited Financial Results of the Company for the first quarter ended June 30, 2021 and the same is being uploaded on the website of the Company and is available in the following web link.<BR> <BR> https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/<BR>",
            "news_id": "bb086df3-fcd6-4967-85d7-a86c7c76beb9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=89e840e5-fd92-4d12-8935-2ea9f2967c17.pdf",
            "news_date": "2021-08-25 18:25:33",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated August 7, 2021 wherein we have intimated the schedule of Investors/ Analysts call on August 13, 2021.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first quarter ended June 30, 2021.  The presentation is also being uploaded in the following web-link of the Company.",
            "news_id": "4927d679-33b1-4f8e-8221-1f34121e8040",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c466fb4d-b9a9-4731-8051-e46df3f4e152.pdf",
            "news_date": "2021-08-12 20:02:08",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For First Quarter Ended June 30, 2021",
            "news_body": "The Board of Directors of the Company at its meeting held today, August 12, 2021, has inter alia, considered and approved the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.",
            "news_id": "76111d10-a19b-4f27-806d-ac23861f9e03",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=120bdacd-3987-4dee-b8ae-b5cfa1293e8d.pdf",
            "news_date": "2021-08-12 19:37:58",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "The Board of Directors of the Company at its meeting held today, August 12, 2021, has inter alia, considered and approved:-<BR> <BR> 1.  the Un-audited Financial Results of the Company for the First Quarter ended June 30, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.<BR> <BR> 2.  an Interim Dividend @ 150% i.e. Rs.1.50 (Rupee one and paise fifty) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2021-22. <BR> <BR>",
            "news_id": "42d43ea5-d7ea-44e2-abe7-6efb0e04d10f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef5c7bdf-62e2-4834-9fc6-7d0683d6eb13.pdf",
            "news_date": "2021-08-12 18:57:27",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated May 28, 2021 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2021. We are attaching herewith the Transcript of the analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021 and the same is being uploaded on the website of the Company and is available in the following web link.<BR> <BR> https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/<BR>",
            "news_id": "d1c0b52e-58e7-4676-9af2-dbfcf46f9876",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=58f1f8e9-8272-46db-8bca-1f3c8434a55f.pdf",
            "news_date": "2021-06-11 11:45:08",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please refer to our letter dated May 28, 2021 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2021.  In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021.  The presentation is also being uploaded in the following weblink of the Company.<BR> <BR> <BR>",
            "news_id": "3c4469e6-6f4e-43ca-8807-61dc85db434f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31e9debd-32d4-4350-a71e-3b0e06cfd30b.pdf",
            "news_date": "2021-05-31 15:37:09",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Fourth Quarter And Year Ended March 31, 2021",
            "news_body": "The Board of Directors of the Company at its meeting held today, May 31, 2021, has inter alia, considered and approved the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors. Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditors of the Company, M/s. B S R & Associates LLP, Chartered Accountants, have issued the audit report on Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2021 with unmodified opinion.<BR> We also enclose a copy of the Press Release on Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2021.<BR>",
            "news_id": "b978da9a-a5e2-4305-99c2-4c3c8f00d461",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6041cff3-6bc0-4758-92c1-e7528c3b98eb.pdf",
            "news_date": "2021-05-31 13:32:29",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting",
            "news_body": "The Board of Directors of the Company at its meeting held today, May 31, 2021, has inter alia, considered and approved Audited Financial Results for the fourth quarter and year ended 31.03.2021 and other matters.",
            "news_id": "b56eb418-3d65-4f81-a187-570a81474ac2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc02b5d5-f0b1-4299-a022-16f0d3198062.pdf",
            "news_date": "2021-05-31 13:10:59",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "AUROPHARMA",
            "disp": "Aurobindo Pharma",
            "bse_code": 524804,
            "isin": "INE406A01037",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please refer to our letter dated February 9, 2021 wherein we have intimated the schedule of Investors/ Analysts call on February 11, 2021. We are attaching herewith the Transcript of the analyst / investor call on the Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2020 and the same is being uploaded on the website of the Company and is available in the following web link.<BR> <BR> https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/<BR>",
            "news_id": "b3551889-5ffb-44ce-90e8-899ddf06408e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98656a6d-19d8-42c5-befc-955dbbb4254a.pdf",
            "news_date": "2021-02-25 10:29:59",
            "seo": "aurobindo-pharma-ltd",
            "ltp": 1146.6,
            "ch": 22.5,
            "pch": 2.0016012810248203,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 275,
            "exch": "NSE",
            "seg": "E"
        }
    ],
    "remarks": ""
}